Trial reportThe British journal of ophthalmology2023
Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS).
Trial report in The British journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 5 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Efficacy of interventions for myopia control in children: A systematic review with network meta-analyses.Acta ophthalmologica · 2025Pooled it
- A systematic review of the study design and statistical practices in randomized controlled trials on myopia treatment (2019-2023).BMC ophthalmology · 2025Pooled it
- Efficacy of spectacle lenses specifically designed for myopia control: systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Pooled it
- Interventions for myopia control in children: a living systematic review and network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Myopia management algorithm. Annexe to the article titled Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute.European journal of ophthalmology · 2024Guideline
- Evaluating the effect of a new myopia control spectacle lens among children in Israel: 24-month results.Eye (London, England) · 2026Trial
- Diffractive optical element (D.O.E) spectacle lenses for myopia prevention and control: a small-scale pilot study among younger Chinese children.BMJ open ophthalmology · 2026Trial
- The Impact of Myopia Control Spectacle Lens Designs on Visual Function.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Trial
- Slowing myopia progression with cylindrical annular refractive elements (CARE) spectacle lenses-Year 1 results from a 2-year prospective, multi-centre trial.Acta ophthalmologica · 2025Trial
- New design peripheral defocus spectacle lens vs. single-vision for slowing myopia progression in children: randomized controlled trial.Scientific reports · 2025Trial
- Effect of Increased Power and Asphericity of Highly Aspherical Lenslets on Myopia Control Efficacy: A Contralateral Crossover Study.Translational vision science & technology · 2025Trial
- Defocus Incorporated Multiple Segments (DIMS) spectacle lenses in UK children: Outcomes from a 2-year multi-site interventional trial.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Trial
- Myopia control efficacy of individualised ocular refraction customisation spectacle lenses: A 2-year follow-up study.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Trial
- Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One-year results.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Trial
- Axial Growth and Myopia Progression After Discontinuing Soft Multifocal Contact Lens Wear.JAMA ophthalmology · 2025Trial
- Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS).BMJ open ophthalmology · 2024Trial
- The Impact of Back Optic Zone Design in Orthokeratology on Visual Performance.Translational vision science & technology · 2024Trial
- Low-Concentration Atropine for Myopia Management: Recent Evidence and Clinical Implications.Ophthalmology and therapy · 2026Review
- Effect of Switching Myopia Control Strategies on Axial Elongation in Children with Poor Response to Highly Aspherical Lenslet Therapy.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- Optical isoplanatic patch size across the visual field as a function of wavelength, pupil size, and accommodation in emmetropic and myopic eyes.Biomedical optics express · 2026Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMutations in the L/M cone opsin gene array cause abnormally high perceived retinal contrast and the development of myopia. Environmental factors may also lead to high visual contrast and cause myopia. Diffusion optics technology (DOT) lenses are designed to reduce contrast signalling in the retina and slow myopia progression.
methodsThe
results256 children (58% female; mean age at screening, 8.1 years) were dispensed spectacles. Across all groups, baseline averages were AL 24.02 mm (SD±0.77 mm), SER -2.01 D (SD±0.9 D) using manifest refraction, and SER -1.94 D (SD±1.0 D) using cycloplegic autorefraction. At 12 months, mean difference in SER progression for test 1 versus control was -0.40 D (p<0.0001), representing a 74% reduction and -0.32 D for Test 2 (p<0.0001), representing a 59% reduction. The difference in AL progression for test 1 versus control was 0.15 mm (p<0.0001) and test 2 versus control was 0.10 mm (p=0.0018).
conclusion12-month results from this ongoing trial demonstrate the safety and effectiveness of DOT spectacles for reducing myopic progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.